Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 Protease Inhibitor
JE-2178 is an orally bioavailable inhibitor of HIV-1 protease, exhibiting potent antiviral activity. With an IC50 value of 15 nM and a Ki value of 0.318 nM, JE-2178 effectively targets the protease enzyme critical for viral replication. This compound is valuable for research applications focused on HIV-1 inhibition and the development of antiretroviral therapies. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-7 is a selective inhibitor of the HIV-1 protease, exhibiting an IC50 of 3.52 nM and an EC50 of 37 nM. This compound demonstrates potent antiviral activity, making it a valuable tool in the study of HIV-1 replication and protease function. Its efficacy positions it as a useful reagent for research applications aimed at developing antiviral therapies against HIV-1. -
HIV Protease Inhibitor
Kynostatin 272 is a potent inhibitor of the HIV protease, targeting the enzyme's active site by mimicking the substrate transition state. This mechanism effectively disrupts a critical stage in the replication cycle of the HIV virus. Kynostatin 272 serves as a valuable tool in HIV research, aiding in the development of therapeutic strategies for managing HIV and AIDS. -
HIV Protease Inhibitor
Stercobilin hydrochloride (mixture of isomers) serves as an HIV protease inhibitor, exhibiting a Ki value of 4 μM. This bile pigment, derived from gut bacteria metabolism, can promote pro-inflammatory responses in mouse macrophage RAW264 cells, including the upregulation of cytokines such as TNF-α and IL-1β. Applications of Stercobilin hydrochloride extend to the investigation of inflammatory processes and viral infections. -
HIV Protease Inhibitor
GS-9770 is an orally active inhibitor specifically targeting HIV protease, with a Ki of 0.16 nM. It demonstrates potent antiviral activity against both HIV-1 and HIV-2 strains, showing EC50 values ranging from 1.9 to 26 nM. In addition to its efficacy, GS-9770 is metabolically stable in human liver microsomes and exhibits favorable pharmacokinetic properties in Sprague Dawley rats, making it a valuable tool for research in HIV treatment. -
HIV Protease Inhibitor
L 756423 is a potent inhibitor of HIV protease, targeting the enzyme crucial for the maturation of infectious HIV particles. This compound exhibits significant antiviral activity, making it a valuable tool for research into HIV infection and the development of therapeutic strategies. Its effective inhibition of protease could contribute to understanding HIV lifecycle and resistance mechanisms. -
HIV Protease Inhibitor
R-87366 is a water-soluble inhibitor of HIV protease, demonstrating potent inhibition with a Ki value of 11 nM. This compound is instrumental in the study of human immunodeficiency virus (HIV) mechanisms and provides valuable insights for the development of antiviral therapies. R-87366 serves as a key reagent for research focused on combating HIV infections. -
HIV Protease Inhibitor
Lopinavir Metabolite M-1 is a potent HIV protease inhibitor with a Ki of 0.7 pM. This active metabolite exhibits significant antiviral activity in vitro, making it valuable for research on HIV treatment and drug resistance mechanisms. Its efficacy in inhibiting HIV replication underlines its relevance in antiviral studies and therapeutic development. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-2 is a highly potent inhibitor of HIV-1 protease, exhibiting an IC50 of 2.53 nM. This compound demonstrates significant antiviral activity against both DRV-sensitive and DRV-resistant strains of HIV-1. It is a valuable tool for researching antiretroviral therapies and understanding HIV resistance mechanisms. -
HIV-1 Protease Inhibitor
8-Prenylluteone is an HIV-1 protease inhibitor that demonstrates significant antiviral activity with an IC50 value of 4 μM. This compound is utilized in research focused on HIV-1 replication and its inhibition, making it a valuable tool for studying the effects of protease inhibition on viral pathogenesis and potential therapeutic strategies. -
HIV Protease Inhibitor
HIV protease-IN-1 is a potent non-peptidic inhibitor of HIV protease, designed to interfere with the viral life cycle. Its primary mechanism involves the inhibition of HIV protease, which is essential for the processing of viral polyproteins into functional proteins. This compound holds significant potential for research applications in the development of therapeutic strategies against AIDS and HIV-related pathologies. -
Renin/HIV-1 Protease Inhibitor
PD 134922 is a potent inhibitor of renin and HIV-1 protease, exhibiting an IC50 of 15 nM against HIV-1 protease. This compound is valuable in studies focused on the modulation of blood pressure regulation through renin inhibition and provides insights into HIV-1 protease activity. Its application extends to research in antiviral therapies and blood pressure-related disorders, making it a useful tool for scientists in pharmacological studies. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-12 is a potent inhibitor of HIV-1 protease, exhibiting an IC50 of 0.51 nM. This compound effectively targets both wild-type and drug-resistant variants of the enzyme, making it a valuable tool in HIV research. Its primary applications include the study of HIV-1 protease function and the development of antiviral therapies. -
HIV-1 PR/RT Inhibitor
HIV-1 inhibitor-53 is a dual inhibitor targeting HIV-1 protease (PR) and reverse transcriptase (RT). It demonstrates potent inhibitory activity with IC50 values of 1.93 nM for PR and 2.35 μM for RT, making it an important tool for studying HIV replication. This compound is suitable for research applications related to acquired immune deficiency syndrome (AIDS) and the development of antiretroviral therapies. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-8 is a potent inhibitor of HIV-1 protease, exhibiting an IC50 value of 0.32 nM. This compound effectively inhibits wild-type HIV-1 (HIV-1NL4-3) with an IC50 of 0.29 μM and a drug-resistant variant (HIV-1MDR) with an IC50 of 1.90 μM. Its strong antiviral activity against both strains makes HIV-1 protease-IN-8 a valuable tool for research in HIV treatment and drug resistance studies. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-5 is a potent inhibitor of HIV-1 protease, exhibiting an IC50 of 1.64 nM. This compound demonstrates significant efficacy against both wild-type and darunavir-resistant variants of HIV-1, making it a valuable tool for antiviral research. Its mechanism of action is crucial for developing therapeutic strategies to combat HIV-1 infections and resistance. -
HIV-1 Protease Inhibitor
Longipedunin A is a potent inhibitor of HIV-1 protease, exhibiting an IC50 value of 50 µg/mL. This compound effectively interferes with the proteolytic processing of viral polyproteins, thereby limiting HIV-1 replication. Longipedunin A is suitable for research applications in virology and studies focused on developing antiviral therapies. -
HIV-1 Inhibitor
U-75875 is an HIV-1 protease inhibitor that effectively impedes the processing of Gag-Pol proteins, thereby disrupting viral maturation and replication. This compound is primarily utilized in research focused on HIV-1 infection, providing valuable insights into viral life cycle mechanisms and potential therapeutic interventions. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-11 is a potent HIV-1 protease inhibitor with an IC50 value of 0.41 nM. This compound demonstrates significant efficacy against drug-resistant variants of the virus, offering opportunities for HIV research and therapeutic development. Its selective targeting of the HIV-1 protease positions it as a valuable tool in the study of HIV replication and infection mechanisms. -
HIV Proteinase Inhibitor
AG-1284 is an effective HIV proteinase inhibitor, demonstrating an EC50 of 0.5 mg/mL. This compound is utilized in research focused on HIV infection mechanisms and therapeutic strategies aimed at viral suppression. AG-1284's inhibition of HIV proteinase makes it a valuable tool for studying the virus's replication cycle and potential drug development. -
HIV Protease Inhibitor
A-77003 is a potent HIV protease inhibitor, demonstrating an IC50 range of 0.1 to 0.2 μg/ml against both HIV-1 and HIV-2 proteases. This compound exhibits significant antiretroviral activity while maintaining low cytotoxicity in vitro, making it suitable for research applications focused on HIV treatment and therapeutic development. -
HIV-1 Protease Inhibitor
A 74704 is a pseudo C2-symmetric inhibitor targeting HIV-1 protease. This compound effectively disrupts the enzymatic activity of the protease, thereby inhibiting viral replication. It serves as a valuable reagent for studying HIV pathogenesis and developing antiviral therapies. -
HIV-1 Protease Inhibitor
A-80987 is a selective inhibitor of human immunodeficiency virus type 1 (HIV-1) protease. This compound effectively disrupts the proteolytic processing of viral polyproteins, thereby hindering viral replication. A-80987 is valuable for research focused on HIV pathogenesis and therapeutic interventions targeting viral enzyme activity. -
HIV-1 Reverse Transcriptase Inhibitor
Opaviraline is a potent HIV-1 reverse transcriptase inhibitor. It effectively disrupts the viral replication process by targeting the reverse transcriptase enzyme, which is crucial for converting viral RNA into DNA. This compound is utilized in research focused on developing antiviral therapies and understanding HIV-1 resistance mechanisms. -
HIV Protease Inhibitor
Ro 31-8588 is a potent HIV protease inhibitor, exhibiting a Ki of 0.3 nM. This compound is essential for studying the role of HIV protease in viral replication and can be utilized in research focused on AIDS treatment and potential therapeutic strategies. Its high affinity makes it a valuable tool for investigating the mechanistic aspects of HIV inhibition. -
HIV-1 Protease Inhibitor
LY-289612 is a potent HIV-1 protease inhibitor, exhibiting an IC50 value of 1.5 nM. This compound effectively disrupts the proteolytic processing of viral polyproteins, thereby inhibiting the replication of HIV-1. It is utilized in research focused on developing antiviral therapies and understanding HIV resistance mechanisms. -
HIV-1 Protease Inhibitor
PL-100 is a powerful inhibitor of HIV-1 protease, exhibiting a Ki of 36 pM and an EC50 of 16 nM. This compound effectively inhibits viral replication by targeting HIV-1 protease activity, showing significant antiviral efficacy against drug-resistant strains of the virus. PL-100 is suitable for research applications focused on understanding and combating drug-resistant HIV infections. -
Bacterial Inhibitor
2-C-Methyl-D-erythritol 4-phosphate is an intermediate in the methylerythritol phosphate (MEP) pathway, primarily present in prokaryotes. This compound plays a crucial role as a precursor in the biosynthesis of isoprenoids and non-isoprenoids, including essential vitamins. Its unique presence in bacteria, coupled with its absence in humans, positions it as a promising target for the development of bacterium-specific therapeutic agents for infectious disease treatment. -
Bacterial Inhibitor
Ianthelliformisamine A TFA is a bacterial inhibitor that enhances antibiotic efficacy against resistant Gram-negative bacteria. It demonstrates potent bactericidal activity against Staphylococcus aureus, with an IC50 value of 3.8 μM and a minimum inhibitory concentration of 25 μM. The biological activity is attributed to the structural variations of its synthetic derivatives and their interaction with various amino ester derivatives, making it a valuable tool for research in antibiotic resistance and bacterial infections. -
Bacterial Inhibitor
Lysine hydroxamate is an amino acid hydroxamate that acts as a bacterial inhibitor by selectively reducing the growth of Escherichia coli K-12. This compound demonstrates significant antibacterial activity among amino acid hydroxamates, with a unique mechanism of action that allows for the reversible inhibition of bacterial growth through the addition of L-serine. Lysine hydroxamate provides a valuable tool for researchers investigating bacterial growth inhibition and exploring amino acid analogs in microbial studies. -
Bacterial Inhibitor
Negamycin is a bacterial inhibitor that targets protein synthesis by binding to the head domain of the bacterial ribosomal small subunit. This interaction disrupts normal translation, leading to cell death and enhancing the misreading of near-cognate codons. Negamycin is valuable for research applications focused on understanding antibiotic mechanisms and bacterial resistance. -
Bacterial Inhibitor
3-Fluoro-DL-valine is an unnatural amino acid that functions as a bacterial inhibitor by disrupting protein synthesis in targeted bacterial strains. This compound demonstrates significant antibacterial activity, making it a valuable tool in microbiological studies. Additionally, 3-Fluoro-DL-valine can be utilized in peptide synthesis, offering versatile applications for the development of bioactive peptides in biochemical research and drug discovery. Its distinct structural properties position it as a promising candidate for innovative compound research and development. -
Bacterial Inhibitor
WQ3810 is a fluoroquinolone antibiotic that acts by inhibiting bacterial DNA gyrase and topoisomerase IV, critical enzymes for DNA replication and transcription. This compound exhibits potent antibacterial activity against a range of gram-positive and gram-negative bacteria. WQ3810 is valuable for research applications focused on studying bacterial infections and developing effective antimicrobial therapies. -
Bacterial Inhibitor
Vebufloxacin is a synthetic antibacterial agent that targets bacterial DNA gyrase, leading to the inhibition of bacterial DNA replication and transcription. It demonstrates potent activity against both gram-positive and gram-negative bacteria, making it a valuable tool in studying bacterial infections and resistance mechanisms. Research applications include evaluating the efficacy of antibacterial treatments and understanding the molecular basis of bacterial survival. -
Bacterial Inhibitor
BO3482 is a bacterial inhibitor that exhibits antimicrobial activity against methicillin-resistant Staphylococci (MRS). It demonstrates a minimum inhibitory concentration (MIC90) of 6.25 mg/mL, effectively halting bacterial growth. This compound is valuable for research applications focused on antibiotic resistance and the development of new antibacterial agents. -
Bacterial Inhibitor
A7132 is a potent antibacterial agent that targets bacterial infections. This compound exhibits broad-spectrum antibacterial activity, making it a valuable tool for research applications in antimicrobial studies and the development of new therapies against bacterial resistance. A7132 is suitable for evaluating the efficacy of antibacterial compounds in various biological assays. -
β-lactamase inhibitor
ETX0282 is a β-lactamase inhibitor that functions as an orally active prodrug, converted in the liver to its active form, ETX1317. This compound demonstrates excellent stability during intestinal absorption and enhances the efficacy of antibiotics, like Cefpodoxime Proxetil, in reducing bacterial load in models of neutropenic infections. ETX0282 is useful for research focused on combating infections caused by drug-resistant Gram-negative bacteria. -
Beta-lactamase Inhibitor
Doxazosin impurity 12 is identified as a CTX-M β-lactamase inhibitor, exhibiting a Ki value of 0.7 mM against the CTX-M enzyme. This compound is valuable for research applications aimed at overcoming antibiotic resistance mediated by β-lactamases, particularly in the study of bacterial infections and the development of novel antimicrobial strategies. -
Metallo-β-Lactamase Inhibitor
Metallo-β-lactamase-IN-14 is a potent inhibitor of metallo-β-lactamases, specifically targeting VIM-1 and VIM-2 enzymes. This compound demonstrates significant antibacterial activity against Gram-negative bacteria, including Pseudomonas aeruginosa. It is a valuable tool for research applications aimed at combating resistance in clinical pathogens. -
Metallo-β-Lactamase Inhibitor
Metallo-β-lactamase-IN-13 is a potent inhibitor of metallo-β-lactamases, targeting enzymes that confer resistance in Gram-negative bacteria. This compound demonstrates significant antibacterial activity against Pseudomonas aeruginosa, making it an important tool for research into combating antibiotic resistance. Its broad-spectrum activity against various metallo-β-lactamases supports investigations into novel therapeutic strategies for treating resistant bacterial infections. -
β-lactamase II Inhibitor
N-Cbz-D-Cysteine is a potent inhibitor of β-lactamase II with a Ki value of 20.1 µM. This compound can be utilized in the study of antibiotic resistance mechanisms and the development of novel β-lactamase inhibitors. N-Cbz-D-Cysteine's biological activity makes it a valuable reagent in research focusing on antimicrobial strategies and enzymatic inhibition. -
β-lactamase II Inhibitor
N-Cbz-L-Cysteine is a potent inhibitor of β-lactamase II, demonstrating a Ki value of 97 µM. This compound is useful in biochemical research aimed at overcoming antibiotic resistance by targeting β-lactamase enzymes. N-Cbz-L-Cysteine may be employed in studies exploring the inhibition of β-lactamase-mediated antibiotic degradation and enhancing the efficacy of β-lactam antibiotics. -
Beta-lactamase Inhibitor
Xeruborbactam isoboxil is a novel beta-lactamase inhibitor that effectively targets and inhibits the activity of various beta-lactamases. Its primary mechanism involves the binding to the active site of these enzymes, preserving the efficacy of beta-lactam antibiotics. This compound is particularly valuable in combating antibiotic resistance and is utilized in research focused on understanding and overcoming beta-lactam resistance in bacterial infections. -
β-lactamase Inhibitor
GT-055 is a potent β-lactamase inhibitor that demonstrates broad-spectrum activity against a variety of β-lactamase enzymes. This compound effectively enhances the efficacy of β-lactam antibiotics by preventing their hydrolysis, making it a valuable tool in combating antibiotic resistance. GT-055 is suitable for research applications focused on understanding β-lactamase mechanisms and developing new therapeutic strategies. -
Metallo-β-lactamases (MBLs) Inhibitor
epi-D-Captopril is a stereoisomer of Captopril that serves as an inhibitor of metallo-β-lactamases (MBLs). It demonstrates inhibitory activity with IC50 values against NDM-1, IMP-1, and VIM-2 of 64 μM, 173 μM, and 5.5 μM, respectively. This reagent is useful for research applications focused on understanding and addressing drug-resistant bacterial infections associated with MBLs. -
Beta-lactamase Inhibitor
ANT431 is a metallo-β-lactamase inhibitor that enhances the efficacy of beta-lactam antibiotics, particularly Meropenem. This compound is designed for applications in combating antibiotic resistance by restoring the effectiveness of β-lactam antibiotics in bacterial infections, specifically in models involving Escherichia coli. Its potential utility in therapeutic contexts makes it a valuable reagent for microbiological and pharmacological research. -
β-lactamase Inhibitor
Izumenolide is a potent β-lactamase inhibitor derived from the strain Micromonospora chalcea subsp. izumensis. It exhibits significant inhibitory activity against certain β-lactamases, with an IC50 value of 0.01 μg/mL specifically for TEM-2 β-lactamase. This compound is valuable for research applications focused on antibiotic resistance and the development of new therapeutic strategies targeting bacterial infections. -
Influenza Viru Inhibitor
(E/Z)-RA-0002034 is an inhibitor targeting the protease activity of the Chikungunya virus (CHIKV) nsP2, with an IC50 value of 58 nM. This compound covalently modifies the catalytic cysteine residue in a site-specific manner, leading to the inhibition of viral replication. It serves as a valuable tool for studying CHIKV biology and developing antiviral therapies against Chikungunya virus infections. -
HIV Replication Inhibitor
PMEDAP is a potent inhibitor of human immunodeficiency virus (HIV) replication, demonstrating significant antiviral activity. In addition to its efficacy against HIV, PMEDAP exhibits anti-murine cytomegalovirus (MCMV) properties and effectively inhibits Moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality. This compound is valuable for research applications focused on viral pathogenesis and therapeutic interventions in retroviral infections. -
HSV/MCMV Inhibitor
Rociclovir is an acyclic nucleoside derivative that functions as an inhibitor of herpes simplex virus (HSV) and murine cytomegalovirus (MCMV). It has demonstrated protective effects in murine models against HSV and MCMV infections. However, it is important to note that Rociclovir exhibits limited antiviral activity in cell culture systems, highlighting its primary utility in in vivo research applications.
